Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...
Crypto market behavior in 2026 reflects a clear change in priorities. Attention cycles still exist, but sustained interest increasingly tracks projects that dem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results